Benzinga | Nov 6, 2020 10:33AM EST

SVB Leerink Maintains Outperform on FibroGen, Raises Price Target to $92

SVB Leerink maintains FibroGen (NASDAQ:FGEN) with a Outperform and raises the price target from $90 to $92.